26 / 59
PAIN PROGRESSION IN PROSPER TRIAL
Attard G, et al. J Clin Oncol 36, 2018 (suppl; abstr 5043)
hville, TN, USA
calculated on the number
6
1
7
1
Week
177
amide unadjusted
unadjusted
amide adjusted
adjusted
Figure 6. Time to c
CI=confidence interval; E
Assessment of Cancer The
Enzalu
Domain Num
PWB
SWB
EWB
FWB
PCS
PCSP
FAPSI
TOI
FACT-G
FACT-P total
Figure 4. Proportion of patients with pain progression (BPI-SF item 3: worst pain)
Results represent minimum and maximum proportions across a range of BPI-SF scores: worst pain, least pain, average pain, current pain, pain
severity, and pain interference.
BPI-SF=Brief Pain Inventory, Short Form.
Week 17
0
30
Patients, %
Week 33
Week 49
Week 65
Placebo
Enzalutamide
Week 97
Week 81
816
718
621
522
355
428
404
Enzalutamide
Placebo
329
239
183
90
139
25
20
15
10
5
Number of patients with data at visit